普拉克索对帕金森病患者认知功能及IGF-1、GABA、Hcy水平的影响

Effects of Pramipexole on Cognitive Function and Levels of IGF-1,GABA and Hcy in Patients with Parkinson's Disease

目的分析帕金森病患者应用普拉克索治疗对其认知功能及IGF-1、GABA、Hcy水平的改善作用。方法研究在64例样本中进行,收录地点:本院,确保所有患者均为帕金森病患者,分组可根据随机数字表法进行,以相等比例分为A组(32例)(美多芭)、B组(32例)(对照组+普拉克索),收录时间:2021年3月至2023年3月。所有纳入患者均接受3个月药物治疗。对比两组所有指标数据。结果A、B组(治疗后)总有效率比较,B组更优;B组、A组(治疗前、后)NMSS、UPDRS评分、血清Hcy水平比较,均降低,且B组更低;B组、A组(治疗前、后)MMSE评分、血清IGF-1、GABA水平比较,均升高,且B组更高(P<0.05)。A、B两组(治疗期间)不良反应总发生率比较,差别不大(P>0.05)。结论对于帕金森病患者,应用普拉克索治疗效果显著,可改善其认知功能,缓解临床症状,调节神经系统和情绪,安全性高。

Objective To analyze the effects of pramipexole on cognitive function and the levels of IGF-1,GABA and Hcy in patients with Parkinson's disease.Methods The study was conducted in 64 samples,which were collected in our hospital to ensure that all patients were Parkinson's disease patients,and the grouping could be carried out according to the random number table method.They were divided into the group A(32 cases)(Medoba)and the group B(32 cases)(control group+pramipexole)in equal proportion,and the enrollment time was from March 2021 to March 2023.All patients were treated with drugs for 3 months.All the index data of the two groups were compared.Results The total effective rate of the group A and the group B was compared,and the group B was better.Compared with the group B and the group A(before and after treatment),NMSS,UPDRS score and serum Hcy level all decreased,and the group B was even lower.Compared with the group B and the group A(before and after treatment),MMSE score,serum IGF-1 and GABA levels all increased,and the group B was higher(P<0.05).There was no significant difference in the total incidence of adverse reactions between the group A and the group B(during treatment)(P>0.05).Conclusion For patients with Parkinson's disease,pramipexole is effective,which can improve their cognitive function,relieve clinical symptoms,regulate nervous system and mood,and has high safety.